Aprea Therapeutics, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Oren Gilad
- Full Time Employees
- 8
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 535 Boylston St. Boston MA United States of America 02116
- IPO Date
- Oct 3, 2019
- CIK
- 0001781983
- Website
- atrinpharma.com
- Similar Companies
- Business
- Aprea Therapeutics, Inc. (Nasdaq: APRE) is a clinical-stage biopharmaceutical company focused on developing and commercializing novel synthetic lethality-based cancer therapeutics that target DNA damage response (DDR) pathways in oncology. Founded in 2006 and headquartered in Doylestown, Pennsylvania, the company exploits cancer cell mutations to selectively kill tumors while minimizing toxicity to healthy cells; its lead product candidates include APR-1051, an oral small-molecule WEE1 kinase inhibitor in Phase 1 ACESOT-1051 trial for advanced solid tumors with CCNE1/CCNE2 amplification, FBXW7/PPP2R1A alterations or HPV+ status, and ATRN-119, a macrocyclic ATR inhibitor in Phase 1/2a ABOYA-119 trial for advanced solid tumors with ATM loss-of-function mutations, both administered orally as monotherapy with potential combination strategies. Aprea targets multiple solid tumor indications such as ovarian, colorectal, prostate, breast, uterine serous carcinoma, head and neck squamous cell carcinoma and KRASG12/13 & TP53-mutated colorectal cancer; it conducts global clinical development primarily in North America and Europe through collaborations with academic centers including MD Anderson Cancer Center. In May 2022, Aprea acquired Atrin Pharmaceuticals, integrating ATRN-119, APR-1051 (formerly ATRN-W1051) and related DDR platform technologies, shifting strategic focus to synthetic lethality; recent advancements encompass first patient dosing in ACESOT-1051, recommended Phase 2 dose establishment for ATRN-119, Cohort 5 enrollment for APR-1051 with safety/efficacy data anticipated H1 2026, a March 2025 agreement with MD Anderson to explore APR-1051 in HPV+ head and neck squamous cell carcinoma, June 2025 preclinical anti-proliferative results for APR-1051 in such cancers, and a Q1 2024 private placement of up to $34 million led by Sphera Healthcare to fund operations into 2026.
Aprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid Tumors
Aprea Therapeutics (APRE) Upgraded to Buy: Here's What You Should Know
Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
Here Are Thursday’s Top Wall Street Analyst Research Calls: Alcoa, Chiron Real Estate, Clear Secure, Fortinet, Fresh Pet, Kennametal, Oracle, PayPal, United Therapeutics, and More
Aprea Therapeutics to Provide Clinical Update on ACESOT-1051 Phase 1 Trial Evaluating WEE1 Inhibitor, APR-1051, at ASCO 2026 Annual Meeting
Aprea Therapeutics Announces Closing of Oversubscribed $30 Million Private Placement
Aprea Therapeutics Announces Oversubscribed $30 Million Private Placement
Aprea Therapeutics Highlights Positive Emerging Clinical Activity for WEE1 Inhibitor, APR-1051, with a Confirmed Partial Response in the Ongoing Phase 1 ACESOT-1051 Trial
Aprea Therapeutics (APRE) Projected to Post Quarterly Earnings on Tuesday
Aprea Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update
Aprea Therapeutics Advanced Cancer Trial Shows Promising Results, Stock Soars
Aprea Therapeutics Announces Additional Positive Clinical Activity for WEE1 Inhibitor, APR-1051, Including Second Partial Response in Ongoing ACESOT-1051 Trial
Aprea Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
Aprea Therapeutics Strengthens Global Patent Portfolio in DNA Damage Response (DDR) Cancer Therapeutics, Paving Way for Pipeline Growth
Aprea Therapeutics Appoints Industry Veteran Eugene Kennedy, MD, as Chief Medical Advisor
Aprea Therapeutics Announces Early Clinical Proof-Of-Concept in the Ongoing ACESOT-1051 Dose-Escalation Trial Evaluating WEE1 Inhibitor APR-1051, Including Partial Response Observed on First Scan
Aprea Therapeutics Announces $5.6 Million Private Placement Priced At-The-Market Under Nasdaq Rules
New Strong Sell Stocks for January 19th
New Strong Sell Stocks for Jan. 14
Aprea Therapeutics, Inc. (NASDAQ:APRE) Short Interest Down 41.3% in December